HomeCompareDTARF vs JNJ

DTARF vs JNJ: Dividend Comparison 2026

DTARF yields 1408.45% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DTARF wins by $396181116.92M in total portfolio value
10 years
DTARF
DTARF
● Live price
1408.45%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$396181116.95M
Annual income
$347,628,612,125,698.30
Full DTARF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — DTARF vs JNJ

📍 DTARF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDTARFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DTARF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DTARF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DTARF
Annual income on $10K today (after 15% tax)
$119,718.31/yr
After 10yr DRIP, annual income (after tax)
$295,484,320,306,843.56/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, DTARF beats the other by $295,484,320,302,857.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DTARF + JNJ for your $10,000?

DTARF: 50%JNJ: 50%
100% JNJ50/50100% DTARF
Portfolio after 10yr
$198090558.49M
Annual income
$173,814,306,065,193.84/yr
Blended yield
87.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DTARF
No analyst data
Altman Z
-89.5
Piotroski
0/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DTARF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDTARFJNJ
Forward yield1408.45%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$396181116.95M$30.3K
Annual income after 10y$347,628,612,125,698.30$4,689.40
Total dividends collected$392623552.61M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DTARF vs JNJ ($10,000, DRIP)

YearDTARF PortfolioDTARF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$151,545$140,845.07$10,592$272.30+$141.0KDTARF
2$2,156,955$1,994,801.51$11,289$357.73+$2.15MDTARF
3$28,842,699$26,534,757.71$12,123$472.89+$28.83MDTARF
4$362,470,620$331,608,932.15$13,141$629.86+$362.46MDTARF
5$4,282,591,462$3,894,747,898.48$14,408$846.81+$4282.58MDTARF
6$47,588,408,428$43,006,035,563.10$16,021$1,151.60+$47588.39MDTARF
7$497,541,651,942$446,622,054,924.38$18,122$1,588.22+$497541.63MDTARF
8$4,896,368,656,645$4,363,999,089,067.01$20,930$2,228.20+$4896368.64MDTARF
9$45,376,172,736,896$40,137,058,274,285.76$24,792$3,191.91+$45376172.71MDTARF
10$396,181,116,954,177$347,628,612,125,698.30$30,274$4,689.40+$396181116.92MDTARF

DTARF vs JNJ: Complete Analysis 2026

DTARFStock

Delta Resources Limited, an exploration company, engages in the acquisition, exploration, and development of gold and base metal projects in Canada. It has an agreement to acquire a 100% interest in the Delta-1/Eureka project, which consists of 245 mining claims totaling an area of 4,495 hectares located in the Thunder Bay district of Ontario; and the Delta-2 project comprising 237 claims covering an area of 12,650 hectares located in the Chibougamau Mining district of Quebec. The company also holds an option agreement to acquire the Dollier property that consists of 40 claims covering an area of 2,228 hectares located in Chibougamau, Quebec. The company was formerly known as Golden Hope Mines Limited and changed its name to Delta Resources Limited in July 2019. Delta Resources Limited was incorporated in 1946 and is based in Kingston, Canada.

Full DTARF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DTARF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DTARF vs SCHDDTARF vs JEPIDTARF vs ODTARF vs KODTARF vs MAINDTARF vs ABBVDTARF vs MRKDTARF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.